The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 336:775-785 March 13, 1997 Number 11
NextNext

The Management of Hypertrophic Cardiomyopathy
Paolo Spirito, M.D., Christine E. Seidman, M.D., William J. McKenna, M.D., and Barry J. Maron, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Hypertrophic cardiomyopathy is a complex cardiac disease with unique pathophysiologic characteristics and a great diversity of morphologic, functional, and clinical features.1,2,3,4,5,6,7,8 The heterogeneity of the disease is accentuated by the fact that it afflicts patients of all ages. During the past few years, technological developments in implantable defibrillators and pacemakers have provided new therapeutic options for patients with the disease.9,10,11,12,13,14,15,16,17,18 In addition, rapid advances in our knowledge of the molecular defects responsible for hypertrophic cardiomyopathy have deepened our understanding of the disorder and have suggested new approaches to the assessment of prognosis.19,20,21,22 These recent developments, however, have also generated considerable . . . [Full Text of this Article]

Heterogeneity of Clinical and Genetic Features

Treatment of the Symptoms of Heart Failure

Medical Therapy

            Pharmacologic Options

            Strategies for Drug Therapy

            Treatment of Asymptomatic Patients and Prevention of Disease Progression

            Management of Atrial Fibrillation

Treatment Options after the Failure of Drug Therapy

            Surgery for Relief of Outflow Tract Obstruction and Symptoms

            Nonsurgical Techniques for Relief of Outflow Tract Obstruction and Symptoms

Stratification of Risk

Clinical Indicators of Risk

            Major Risk Factors

            Electrophysiologic Testing

            Syncope

            Massive Left Ventricular Hypertrophy

Genetic Indicators of Risk

Prevention of Sudden Death

Amiodarone

Implantable Defibrillators


Source Information

From the Servizio di Cardiologia, Ospedale Sant'Andrea, La Spezia, Italy (P.S.); the Howard Hughes Medical Institute and the Cardiovascular Division, Brigham and Women's Hospital, Boston (C.E.S.); the Department of Cardiological Sciences, St. George's Hospital Medical School, London (W.J.M.); and the Minneapolis Heart Institute Foundation, Minneapolis (B.J.M.).

Address reprint requests to Dr. Spirito at the Servizio di Cardiologia, Ospedale Sant'Andrea, Via Veneto 197, La Spezia 19100, Italy.

References


Related Letters:

The Management of Hypertrophic Cardiomyopathy
Seggewiss H., Gleichmann U., Faber L., Maron B. J., Spirito P., McKenna W. J., Seidman C. E.
Extract | Full Text  
N Engl J Med 1997; 337:349-350, Jul 31, 1997. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.